Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

NCT03248570 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03248570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03248570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
February 20, 2018
Completion date
September 28, 2023
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostatic cancer, metastatic prostate cancer